[Federal Register Volume 74, Number 178 (Wednesday, September 16, 2009)]
[Notices]
[Pages 47594-47595]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-22275]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Docket Number NIOSH-150]
Request for Information on Alternative Duty: Temporary
Reassignment for Health Care Workers Who Work With Hazardous Drugs
AGENCY: National Institute for Occupational Safety and Health (NIOSH)
of the Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of public comment period.
-----------------------------------------------------------------------
SUMMARY: NIOSH intends to publish a Current Intelligence Bulletin (CIB)
on alternative duty and other forms of administrative controls for
health care workers who work with hazardous drugs and are trying to
conceive, are pregnant, and/or are breast feeding. Alternative duty
involves transferring the worker to a similar position, but one in
which they would not be required to handle hazardous drugs.
Exposure to certain hazardous drugs can affect reproduction and
have adverse health effects on the developing fetus. Some hazardous
drugs are known to be present in the breast milk of patients treated
with them [Briggs et al. 2005]. NIOSH plans to develop recommendations
in this CIB on alternative duty and administrative controls that will
protect the workers and their offspring from the potential adverse
reproductive effects of hazardous drugs.
NIOSH is requesting (1) comments and information relevant to the
potential reproductive effects of hazardous drugs, (2) reports or other
data that investigate possible adverse reproductive effects in workers
exposed to hazardous drugs, and (3) information pertaining to
alternative duty policies and administrative controls for workers,
particularly couples trying to conceive and women who are pregnant and
breastfeeding, and who are exposed to hazardous drugs in health care
and other industries.
Public Comment Period: Comments must be received within 60 calendar
days of publication in the Federal Register.
ADDRESSES: You may submit comments, identified by docket number NIOSH-
150, by any of the following methods:
Mail: NIOSH Docket Office, Robert A. Taft Laboratories,
MS-C34, 4676 Columbia Parkway, Cincinnati, OH 45226.
Facsimile: (513) 533-8285.
E-mail: [email protected].
All information received in response to this notice will be
available for public examination and copying at the NIOSH Docket
Office, Room 111, 4676 Columbia Parkway, Cincinnati, Ohio 45226. A
complete electronic docket containing all comments submitted will be
available on the NIOSH Web page at http://www.cdc.gov/niosh/docket, and
comments will be available in writing by request. NIOSH includes all
comments received without change in the docket, including any personal
information provided.
FOR FURTHER INFORMATION CONTACT: Thomas Connor, PhD, NIOSH Robert A.
Taft Laboratories, MS-C23, 4676 Columbia Parkway, Cincinnati, OH 45226,
(513) 533-8399, e-mail [email protected].
SUPPLEMENTARY INFORMATION: Drugs have a successful history in treating
illnesses and injuries, and are responsible for many of our medical
advances over the past century. However, virtually all drugs can have
side effects associated with patient use [NIOSH 2004]. In addition to
risks in patients, workers who handle them are at risk of suffering
these effects. In addition, it is known that exposures to even very
small concentrations of certain drugs may be hazardous for workers who
handle them or work near them. Occupational exposures to hazardous
drugs can lead to adverse reproductive events [NIOSH 2004, Dranitsaris
et al. 2005].
The term ``hazardous drugs'' was first used by the American Society
of Hospital Pharmacists (ASHP) in 1990 and recent updates to their
guidelines [ASHP 2006] and is currently used by NIOSH [2004] and the
Occupational Safety and Health Administration (OSHA) [OSHA 1999]. Drugs
are classified as hazardous if studies in animals or humans indicate
that exposures to them have a potential for causing cancer,
genotoxicity, developmental or reproductive toxicity, or harm to
organs. Many drugs with a hazardous classification are used to treat
illnesses such as cancer (antineoplastic drugs) or HIV infection
(antiviral drugs). See Appendix A of the NIOSH Alert [NIOSH 2004] for
examples of hazardous drugs and a full discussion of criteria used to
define and classify them as hazardous.
The numbers and types of work environments containing
antineoplastic drugs are expanding as these agents are used
increasingly for nonmalignant rheumatologic and immunologic diseases
[NIOSH 2004].
When exposed to hazardous drugs, health care workers face several
health risks, including reproductive risks. A reproductive hazard
affects the reproductive function of women or men or the ability of
couples to have healthy children [HSE 2003]. Some chemicals, including
many hazardous drugs, are considered reproductive hazards because
studies in humans or animals show that exposure to them may affect
fertility, pregnancy outcome, or cause birth defects.
Evidence shows that these drugs have caused adverse reproductive
outcomes in health care workers. For example, nurses and pharmacists
exposed to hazardous drugs at their worksite reported an increase in
adverse reproductive events including spontaneous abortions,
stillbirths, and congenital malformations when compared with unexposed
health care workers [NIOSH 2004]. In addition, some drugs may
negatively affect germ cell (sperm and egg) development [McInnes and
Schilsky 1996].
In the United States, an estimated 8 million health care workers
[BLS 2007] are potentially exposed to hazardous drugs at their
worksites and may be vulnerable to reproductive risks. These workers
include pharmacists and pharmacy technicians, nursing personnel,
physicians, operating room
[[Page 47595]]
personnel, shipping and receiving personnel, waste handlers,
maintenance, housekeeping, and laundry workers, and workers in
veterinary practices who may come into contact with drugs or drug
waste. Health care workers may be exposed to hazardous drugs when they
compound, administer, or dispose of hazardous drugs, clean up spills,
or touch surfaces that are contaminated with these drugs. These
activities frequently create aerosols or generate dust, thus increasing
the risk of exposure [NIOSH 2004]. Skin absorption and inhalation are
the most likely routes of exposure for a health care worker. However,
ingestion (from hand to mouth) or injection through a needle stick or
sharps injury is possible.
When other types of controls, such as engineering controls and the
use of personal protective equipment do not eliminate exposure to
hazardous drugs, alternative duty or re-assignment away from the
potential hazard is a type of administrative control that will help
protect the workers and their offspring from the potential adverse
reproductive effects of hazardous drugs [Saiki et al. 1994; ACOEM 1996;
HSE 2003].
NIOSH seeks to obtain materials, including published and
unpublished reports and research findings, to evaluate mechanisms for
alternative duty and administrative controls and possible reproductive
health risks of occupational exposure to hazardous drugs. Examples of
requested information include, but are not limited to, the following:
(1) Trends in production and use of hazardous drugs over the past
10 years.
(2) Descriptions of procedures with a potential for exposure to
hazardous drugs.
(3) Identification of industries or occupations in which exposures
to hazardous drugs may occur.
(4) Case reports or other health data that investigate possible
adverse reproductive health effects in workers exposed to hazardous
drugs or related animal data (published or peer-reviewed data are
preferred).
(5) Descriptions of work practices and engineering controls,
including costs and effectiveness of control measures being taken, to
reduce or prevent workplace exposure to these drugs.
(6) Educational materials for worker safety or training on the safe
handling of hazardous drugs.
(7) Guidelines and/or recommendations for alternative
duty/temporary reassignment policies in the health care or other
industries where exposures cannot be controlled by conventional methods
(engineering controls etc).
(8) Data pertaining to the need for alternative duty to limit
occupational exposures to hazardous drugs for couples who are tying to
conceive, and women who are pregnant or breastfeeding.
(9) Data pertaining to the feasibility of these types of
recommendations, including actual or projected costs of alternative
duty/temporary reassignment strategies considered.
NIOSH will use this information to determine the need for
developing recommendations for alternative duty/temporary reassignment
for individuals who may be at reproductive risk and/or whose fetus or
offspring may be at risk from exposure to these drugs.
References:
ACOEM (American College of Occupational and Environmental Medicine)
[1996]. Committee report: ACOEM reproductive hazard management
guidelines. JOEM 38(1):83-90.
ASHP [2006]. ASHP guidelines on handling hazardous drugs. Am J
Health-Syst Pharm 63:1172-1193.
BLS [2007]. National Industry-Specific Occupational Employment and
Wage Estimates from BLS, May 2007 [http://www.bls.gov/oes/current/naics2_62.htm#(1)].
Briggs GG, Freeman RK, and Yaffee SJ ed. Drugs in Pregnancy and
Lactation, 7th ed. Lippincott, Williams and Wilkins. Philadelphia,
2005.
Dranitsaris G, Johnston M, Poirier S, Schueller T, Milliken D,
Green E, Zanke B [2005]. Are health care providers who work with cancer
drugs at an increased risk for toxic events? A systematic review and
meta-analysis of the literature. J Oncol Pharm Practice 11:69-78.
HSE (Health and Safety Executive) [2003]. HSE Leaflet. New and
expectant mothers at work; a guide to health professionals. Available
at: http://www.hse.gov.uk/pubns/indg373hp.pdf.
McInnes S, Schilsky RL [1996]. Infertility following cancer
chemotherapy. In: Chabner BA, Longo DL, eds. Cancer Chemotherapy and
Biotherapy: Principles and Practice. 2nd ed. Philadelphia, PA:
Lippincott-Raven, pp. 31-44.
NIOSH [2004]. NIOSH Alert: preventing occupational exposures to
antineoplastic and other hazardous drugs in health care settings.
Cincinnati, OH: U.S. Department of Health and Human Services, Public
Health Service, Centers for Disease Control and Prevention, National
Institute for Occupational Safety and Health, DHHS (NIOSH) Publication
No. 2004-165.
OSHA [1999]. Categorization of drugs as hazardous. In: OSHA
technical manual, TED 1-0.15A, Sec VI, Chapter II. Washington, DC: U.S.
Department of Labor, Occupational Safety and Health Administration
[http://www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.html#2].
Saiki CL, Gold EB, Schenker MB [1994]. Workplace policy on hazards
to reproductive health. In: Gold EB, Laskey BL, Schenker MB, eds.
Occupational Medicine: State of the Art Reviews. Vol 9. Philadelphia,
PA: Hanley & Belfus, Inc, pp. 541-549.
Timpe EM, Motl SE [2004]. Environmental exposure of health care
workers to category D and X medications. Am J Health-Syst Pharm
61:1556-1561.
Dated: September 9, 2009.
John Howard,
Director, National Institute for Occupational Safety and Health,
Centers for Disease Control and Prevention.
[FR Doc. E9-22275 Filed 9-15-09; 8:45 am]
BILLING CODE 4163-19-P